Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 1
2002 5
2003 6
2004 7
2005 8
2006 16
2007 11
2008 10
2009 9
2010 13
2011 8
2012 15
2013 8
2014 10
2015 7
2016 7
2017 8
2018 12
2019 15
2020 16
2021 12
2022 13
2023 17
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

208 results

Results by year

Filters applied: . Clear all
Page 1
The first interim analysis of Italian patients enrolled in the real-world, Pan-European, prospective, observational, phase 4 PEARL study of fremanezumab effectiveness.
Tassorelli C, Barbanti P, Finocchi C, Geppetti P, Kokturk P, Russo A, Sacco S, Cepparulo M; PEARL study group. Tassorelli C, et al. Among authors: geppetti p. Neurol Sci. 2024 May;45(5):2353-2363. doi: 10.1007/s10072-024-07357-3. Epub 2024 Mar 1. Neurol Sci. 2024. PMID: 38424386 Free PMC article. Clinical Trial.
Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study.
Caponnetto V, Russo A, Silvestro M, Tessitore A, De Icco R, Vaghi G, Sances G, Tassorelli C, Baraldi C, Castro FL, Guerzoni S, Prudenzano MP, Fallacara A, Gentile M, Ornello R, Onofri A, Burgalassi A, Chiarugi A, De Cesaris F, Granato A, Casalena A, De Tommaso M, Mampreso E, Merlo P, Coppola G, Battistini S, Rebecchi V, Rainero I, Sepe FN, Dalla Volta G, Sacco S, Geppetti P, Iannone LF; Italian Headache Registry (RICe) Study Group. Caponnetto V, et al. Among authors: geppetti p. CNS Drugs. 2023 Dec;37(12):1069-1080. doi: 10.1007/s40263-023-01050-3. Epub 2023 Nov 24. CNS Drugs. 2023. PMID: 37999868 Free PMC article.
Migraine Treatment: Towards New Pharmacological Targets.
Silvestro M, Iannone LF, Orologio I, Tessitore A, Tedeschi G, Geppetti P, Russo A. Silvestro M, et al. Among authors: geppetti p. Int J Mol Sci. 2023 Jul 31;24(15):12268. doi: 10.3390/ijms241512268. Int J Mol Sci. 2023. PMID: 37569648 Free PMC article. Review.
Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO study.
Vernieri F, Brunelli N, Guerzoni S, Iannone LF, Baraldi C, Rao R, Schiano di Cola F, Ornello R, Cevoli S, Lovati C, Albanese M, Perrotta A, Cetta I, Rossi SS, Taranta V, Filippi M, Geppetti P, Sacco S, Altamura C. Vernieri F, et al. Among authors: geppetti p. J Neurol. 2023 Nov;270(11):5436-5448. doi: 10.1007/s00415-023-11872-2. Epub 2023 Jul 19. J Neurol. 2023. PMID: 37468621
208 results